Molidustat Sodium Drug Asset Due Diligence Report 2026

This Molidustat Sodium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Molidustat Sodium can convert its Small molecule drug profile and HIF-PHs biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Molidustat Sodium (query alias: molidustat)
Modality / target	Small molecule drug; HIF-PHs; HIF-PHs inhibitors
Highest global status	Approved
Originator	Bayer AG
Active developers	Bayer AG

The MCP disease footprint includes Anemia in chronic kidney disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT03543657	Phase 3	Completed	229	The mean Hb level during the evaluation period
NCT04899661	Not Applicable	Active, not recruiting	1081	Incidence of safety events
JPRN-jRCT1071230045	Not Applicable	Complete	42	Effects of sample collection method: Sample collection time, type and amount of sample collected

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial

Phase 3; n=162; evaluation: Positive. Reported fields: Hemoglobin level = 11.70 g/dL (95%CI, 11.50 - 11.90); Hemoglobin level = 11.28 g/dL (95%CI, 11.07 - 11.50)

Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study

Phase 3; n=164; evaluation: Non-inferior. Reported fields: Hemoglobin level = 11.53 g/dL (95%CI, 11.31 - 11.74); Hemoglobin level = 11.67 g/dL (95%CI, 11.48 - 11.85)

Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study

Phase 3; n=51; evaluation: Positive. Reported fields: RR = 54.9 % (95%CI, 40.3 - 68.9)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Molidustat Sodium addresses Anemia in chronic kidney disease. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 21 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: HIF-PHs records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-03-10	HK Innoen and Tanabe Pharma Korea Sign Joint Promotion Agreement for "Badanem Tablets"	Approved	Financial terms not disclosed
2025-12-12	Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)	IND Approval	Financial terms not disclosed
2025-02-20	FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million	Approved	US$220.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Molidustat formulations and methods of use for treatment of anemia in cats”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO